Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-30
2005-08-30
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S206000, C548S214000
Reexamination Certificate
active
06936630
ABSTRACT:
Antiatherosclerotic agents are provided which are represented by Formulas I or II:whereinR iswherein R9, R10, R11, R12, R13, and R14are each, independently, hydrogen or a lower alkyl of 1-6 carbon atoms;R6, and R7are each, independently, hydrogen, lower alkyl of 1-6 carbon atoms, or CH2COOR8, where R8is a lower alkyl of 1-6 carbon atoms; andX is O or S;R1is hydrogen or a lower alkyl of 1-6 carbon atoms;R2, R3, and R4are each, independently, hydrogen or halogen; andR5is a lower alkyl of 1-6 carbon atoms;or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 4387105 (1983-06-01), DeVries et al.
patent: 4387106 (1983-06-01), DeVries et al.
patent: 4623662 (1986-11-01), DeVries
patent: 5185358 (1993-02-01), Creswell et al.
patent: 5420164 (1995-05-01), Tadashi et al.
patent: 5547966 (1996-08-01), Atwal et al.
patent: 2072704 (1993-01-01), None
patent: 2 072 704 (1993-01-01), None
patent: 2 132 771 (1995-04-01), None
patent: 44 38 021 (1996-05-01), None
patent: 0 528 146 (1993-02-01), None
patent: 0 613 894 (1994-09-01), None
patent: A10656350 (1995-06-01), None
patent: 2 384 763 (1978-10-01), None
patent: 2 521 134 (1983-08-01), None
patent: 04 009375 (1992-01-01), None
patent: 8301841 (1995-05-01), None
patent: A19315055 (1993-08-01), None
patent: A19640673 (1996-12-01), None
patent: WO 97/19932 (1997-06-01), None
Barr et al.,Am. J. Med., 11:480-493 (1951).
Gofman et al.,Circulation, 34:679-697 (1966).
Miller and Miller,Lancet, 1:16-19 (1975).
Gordon et al.,Circulation, 79:8-15 (1989).
Stampfer et al.,N. England J. Med., 325:373-381 (1991).
Badimon et al.,Lab. Invest., 60:455-461 (1989).
Miller et al.,Br. Med. J., 282:1741-1744 (1981).
Picardo et al.,Arteriosclerosis., 6:434-441 (1986).
Glomset,J. Lipid Res., 9:155-167 (1968).
Glass et al.,J. Biol Chem., 258:7161-7167 (1983).
MacKinnon et al.,J. Biol. Chem., 261:2548-2552 (1986).
Grow and Fried,J. Biol. Chem., 253:8034-8041 (1978).
Lagocki and Scanu.,J. Biol. Chem., 255:3701-3706 (1980).
Schaefer et al.,J. Lipid Res., 23:1259-1273 (1982).
Cockerill et al.,Arterioscler., Thromb., Vasc. Biol., 15:1987-1994 (1995).
Chemical Abstracts, vol. 116, No. 11, Mar. 16, 1992, Columbus, OH. Abstract No. 105508.
Chemical Abstracts, vol. 58, No. 7, Apr. 1, 1963, Columbus, OH. Abstract No. 7269f.
Chemical Abstracts, vol. 76, No. 9, Feb. 28, 1972, Columbus, OH. Abstract No. 42039.
Chemical Abstracts, vol. 92, No. 13, Mar. 31, 1980, Columbus, OH. Abstract No. 110926.
Crank et al.,J. Med. Chem., 14(11):1075-1077 (1971).
Gauba et al.,Acta Cienc. Indica, Chem., 16C(3):287-294 (1990).
Gupta et al.,Indian J. Pharm. Sci., 41(4):139-140 (1979).
Dhar et al., “Synthesis and Spectroscopic Studies of N-aryl-N′-2-Thiazolylthioureas”,Chemical Abstracts, 81(21):415 (1974), 136038y.
Gheorghiu et al., “Studiul actiunii antituberculoase a unor noi derivati de tiouree (4-metiltiazolintiouree)”,Farmacia, pp. 229-233, Apr. 1962.
Failli Amedeo A.
Steffan Robert J.
Morris Patricia L.
Wyeth
LandOfFree
Substituted 1-aryl-3-heteroaryl-thioureas and substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 1-aryl-3-heteroaryl-thioureas and substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 1-aryl-3-heteroaryl-thioureas and substituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3508081